Lilly continues to build case for prasugrel
Eli Lilly and Co. continued to press its case for regulatory approval of its blood thinner prasugrel today by releasing two more studies offering new analysis of prasugrel’s clinical trial data. The release comes weeks before the U.S. Food and Drug Administration is scheduled to rule on whether the drug should be allowed onto the […]